

Cerenis™

THERAPEUTICS

Half-year report on liquidity agreement with Gilbert Dupont

Under the liquidity contract signed between Cerenis Therapeutics and Gilbert Dupont, the following assets were booked to the liquidity account at 30th June 2017:

- Number of shares: 48,268
- Cash balance in the liquidity account: 155,091.02€

As a reminder, in the last half-year report, at 31st December 2016, the liquidity account stood as follows:

- Number of shares: 23,291
- Cash balance in the liquidity account: : 204,687.69€

About Cerenis: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative lipid metabolism therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess lipids is removed from arteries and is transported to the liver for elimination from the body.

Cerenis is developing a portfolio of lipid metabolism therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).

Cerenis is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development.

CEREN
LISTED
EURONEXT



Contacts:

Cerenis
Jean-Louis Dasseux
CEO
info@cerenis.com
+33 (0)5 62 24 09 49

NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
cerenis@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
cerenis@newcap.eu
+33 (0)1 44 71 94 98